noom glp 1 dosing Noom's GLP-1 Companion Receives Major Update to Prepare for New Expected Prescription Drug Use-Related Software (PDURS) Model GLP-1 Microdosing 2026: 0.1mg Chart

Notably, none of the included trials investigated newer GLP-1 compounds such as tirzepatide, a dual GIP/GLP-1 receptor agonist, or semaglutide

All trials adopted an open-label design, except for the study of Aroda et al., which was a double-blind trial

These side effects are often temporary, but Brello provides ongoing support to manage symptoms and adjust treatment plans as needed

Natural GLP-1 production, while essential for normal glucose homeostasis, is insufficient to treat established metabolic disease

These time-frames were selected based upon the window of THC detection in oral fluid from previous studies 54,55